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Introduction. Cerebral blood flow has been well studied in patients with panic disorder, but only few studies analyzed the
mechanisms underlying the onset of a panic attack. The aim of the present study was to monitor the cerebral hemodynamics
modifications during a panic attack. Materials and Methods. 10 panic disorder patients with recent onset, fully drug na¨ıve, were
compared to 13 patients with panic disorder with a previous history of treatment and to 14 controls. A continuous bilateral
monitoring of mean flow velocities in right and leftmiddle cerebral arteries was performed by transcranial Doppler. Clomipramine
was chosen as challenge. Results. Eight out of 10 patients drug na¨ıve and 6 control subjects out of 13 had a full blown panic attack
during the test, whereas none of the patients with a history of treatment panicked.Theoccurrence of a panic attackwas accompanied
by a rapid decrease of flow velocities in both right and left middle cerebral arteries.Discussion. The bilateral acute decrease of mean
flow velocity during a panic attack suggests the vasoconstriction of themicrocirculation of deep brain structures perfused bymiddle
cerebral arteries and involved in the so-called “fear circuitry,” thus suggesting that cerebral homeostatic dysfunctions seem to have
a key role in the onset of a panic attack.
1. Introduction
Cerebral blood flow (CBF) abnormalities have been reported
in panic disorder (PD). These CBF modifications have
been studied using different imaging techniques: positron
emission tomography (PET) [1–3], single photon emission
computed tomography (SPECT) [4, 5], and functional mag-
netic resonance imaging (fMRI) [6, 7], without a clear
identification of the structures involved. In these studies
the central hypothesis was that blood flow is coupled to
brain activation/deactivation and, therefore, authors chose to
use techniques with a greater spatial resolution in order to
map these events in the brain at the expense of temporal
resolution.
Few studies [8–11] could observe PD patients during a
panic attack (PA) and, of these, only two [10, 11] managed
to describe cerebral activity, using fMRI. Pfleiderer et al. [10]
found a significant increase of activity in the right amygdala
during the onset of a spontaneous PA, whereas Dresler and
colleagues [11] observed that the neuronal dynamics of the
structures involved in the fear network (i.e., amygdala, insula,
and prefrontal cortex) mirrored the description of the attack
made by a patient that experienced a full blown, spontaneous
PA while performing fMRI.
The study of cerebral hemodynamics during the onset
of a PA would be crucial as a certain evidence of different
mechanisms underlying PAs is emerging. However, studying
cerebral hemodynamics during a PA is difficult because of
three factors: (a) it is difficult to pinpoint an occurring PA;
(b) the techniques commonly used to assess brain circulation
are not sensitive to the real time variations; (c) the challenges
commonly used to elicit a PA influence the brain circulation.
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In order to observe unexpected PAs in a clinical setting
and to study their pathophysiology, several panicogenic
agents able to provoke PAs in a controlled laboratory set-
ting have been proposed and widely used: sodium lactate
[12–14], carbon dioxide at different concentrations [15–21],
cholecystokinin [22–27], and serotoninergic agents [28–32].
All these challenges, however, produce intrinsic effects on
cerebral circulation and are therefore inappropriate to study
CBF modifications during a PA.
The idea to use a serotonin reuptake inhibitor (SRI)
as a challenge was generated by the clinical observation
of the so-called biphasic effect, with initial exacerbation of
anxiety, which most patients experience during the first days
of treatment with a SRI [33–37]. Two SRI are available for
intravenous administration in Europe, namely, citalopram
and clomipramine (CMI). To our knowledge, only CMI has
already been used as a challenge. The challenge with CMI
induces neuroendocrine modifications, does not increase
noradrenergic activity, and is sensitive to the effect of sero-
tonin receptors antagonist [38, 39]. CMI, on the other hand,
is the agent with less interference with CBF, compared to the
above-mentioned panicogenic agents [40].
As already stated, PET and SPECT have a low sensibility
in detecting rapid CBF modifications. fMRI, although very
sensitive for cortical areas, is less accurate in detecting deep
brain structures modifications and is expensive and generally
less acceptable to phobic patients.
The transcranial Doppler (TCD) ultrasound technique
is not invasive and allows, with a pulsed emission of low-
frequency ultrasounds, themeasurement of mean flow veloc-
ity (MFV) in the main intracranic arteries [41]. Although
not very sensitive in focusing on specific areas, TCD is
particularly suited to assess rapid flow velocity variations in
real time, in response to challenges. Furthermore TCD is
inexpensive, easy to perform, and totally safe and allows a
continuous and bilateral monitoring of arteries.
CBF abnormalities have been reported using TCD in PD
patients. To our knowledge, however, two are the studies
that performed TCD during a PA [8, 9]. Fontaine et al. [9]
found a bilateral rapid increase of blood flow velocity in the
MCAs, after sodium lactate infusion, greater in patients with
PD compared with healthy controls, whereas Alkin, using
the 35% carbon dioxide challenge, observed an increase in
the basilar artery blood flow velocity [8]. In these studies,
however, continuous TCD monitoring was not performed.
While studying PD patients outside the PA, Owega et al.
[42] found the same variations described above, associated
with significant flow acceleration in the middle and anterior
cerebral arteries and in the left posterior cerebral artery. In
a different study, PD patients showed asymmetric variations
with a highermean blood flow velocity in the rightMCA [43].
A reduction of rightMCAmean flow velocity in patients with
acute and remitted PD was also reported following tilting to
the upright position [44].
In this framework, our hypothesis was that the onset
of a PA is accompanied by rapid blood flow velocities
modifications in theMCAs, as these arteries perfuse the deep
brain structures involved in the fear network.Thus, the aim of
the present study was to monitor the cerebral hemodynamic
ofMCAsduring the onset of a full blownPA, usingTCD.CMI
was chosen as challenge to provoke PAs in a clinical setting
for its slight interference with CBF and because it is safe and
ethically acceptable, being a drug used in the treatment for
PD.
2. Materials and Methodology
Eleven patients meeting the diagnosis of PD according to
Diagnostic and Statistical Manual of Mental Disorders IV
Edition (DSM IV) [45] with recent onset (i.e., within 3
months of the first PA), fully drug naı¨ve, were compared
with 13 patients suffering from PD for longer time, all with
a history of previous treatment, but drug-free for at least two
weeks, and with 14 healthy volunteers.
Exclusion criteria were pregnancy and nursing,
menopause, neurological diseases, mental retardation,
epilepsy, migraine, hypertension, substance abuse, and use
of psychotropic drugs during the two weeks before the test.
All subjects were asked to refrain from smoking and
drinking coffee during the three hours before the study and
to follow a low monoamines diet in the preceding three days.
All the tests were performed in the morning to standardize
the environmental conditions.
Each participant was given detailed information on the
examination and gave their written consent and the protocol
was approved by the local ethic committee.
All the subjects received a careful medical examination
andwere interviewed by the Structured Clinical Interview for
DSM (SCID) [46].
The test, which consisted of four different phases, was
performed as a single-blind study. Each subject was informed
that he would have been injected, in random sequence,
placebo, and CMI.
A commercially available 2MHz pulsed-wave TCD unit
(MultiDop X4, DWL Compumedics) continuously and
simultaneously monitoredmean CBF velocity onMCA bilat-
erally by using the Aaslid technique [41]. Two TCD probes
were fixed over left and right temporal windows by Spencer
helmet.
Starting from an insonation depth of 50mm, depths and
angles of insonation were adjusted to get the best Doppler
signal of the M1 segment for left and right MCAs.
All the participants were informed of the possibility that
they could experience panic symptoms during the test and
were encouraged to continue the test whenever possible.They
were asked not to speak during the monitoring and to signal
the onset of panic/discomfort symptoms justmoving the right
hand.
The first phase (baseline) consisted in Doppler moni-
toring (10 minutes), at rest, until steady MCAs velocities
were attained. During the second phase (placebo) a placebo
infusion of 100mL of saline solution i.v. was administered (14
minutes). The third phase (CMI) consisted in the infusion of
12.5mg of CMI, administered i.v. in 100mL of saline solution
(15 minutes). Finally, during the fourth phase (10 minutes)
(wash), CMI infusion was stopped, continuing Doppler
monitoring until reestablishment of baseline conditions.
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TheTCDmonitoringwas conducted during each phase of the
test.
Before wearing the helmet for TCD monitoring, each
subject completed the following instruments: panic symptom
list (PLS), visual scale of anxiety (VAAS) [47], and state
trait anxiety inventory (STAI) [48]. These scales were also
administered before the commencement of the procedure
and at the end of each phase of the test to evaluate anxiety
and panic symptoms.
Heart and breathing rates were continuously monitored
using a Fukuda Denshi Dynascope device during the entire
examination. The device did not allow data recording. Blood
pressure was measured at the beginning and the end of each
phase of the test.
The test has always been performed by two investigators
in order to continuously control modifications of Doppler
signal and respiratory and heart frequencies.
2.1. Offline Analyses. At the end of the test several offline
analyses were performed. For each subject average values of
MFV, expressed by cm/sec, were calculated for each phase of





) of 7.5 minutes each, taking into
account the latency of the drug effect.
ThehighestMFVvariation during thewhole period of the
test was then measured for each participant.
2.2. Statistics. 𝑡-test for independent samples, chi square test,
and one-way ANOVA were performed when appropriate.
The criteria for PA were occurrence of at least 4 symptoms
described in the PSL and VAAS increase of at least 25mm.
The Statistical Package for the Social Sciences for Win-
dows SPSS (IBM, 2011) version 20.0 was used for data analysis
and results were considered significant when 𝑃 values were
≤0.05.
3. Results and Discussion
3.1. Results. The group of patients with PD with recent onset
was composed of 5 males and 6 females, with a mean age of
26.1 ± 8.2 years; the group of patients suffering from PD for
longer time was composed of 6 males and 7 females, with
a mean age of 32.6 ± 9.0 years; the control subjects were 5
males and 8 females, with a mean age of 28.1 ± 3.4 years.
No statistically significant difference was observed among the
three groups for gender and age.
OnePDpatientwith recent onset and drug na¨ıve reported
great discomfort four minutes after wearing the Spencer
helmet, became restless, and asked to stop the Doppler
monitoring. All the other subjects managed to complete the
four phases of the test. The final sample eligible for statistical
analysis of cerebral hemodinamic was therefore composed
of 10 PD patients with recent onset, 13 PD patients with a
previous history of treatment, and 14 controls.
Eight out of 10 PD patients who were drug na¨ıve
and 6 out of 13 controls had a PA during the test,




MCAL: left middle cerebral artery, MCAR; right middle cerebral artery. 
The arrow shows the beginning of the episode. We can see the mean
flow velocities drop which was rapidly followed by clinical 
manifestations observed by investigators.






Figure 1: Doppler signal during clomipramine infusion: typical
mean flow velocities drop during the onset of a panic attack.
history of treatment panicked. The comparisons were sta-
tistically significant for drug-na¨ıve PD versus PD with
previous treatment (chi square = 15.9, df = 1; 𝑃 = 0.0001) and
for healthy controls versus PD with previous treatment
(chi square = 7.2, df = 1; 𝑃 = 0.0074), while the number of
panickers failed to distinguish significantly drug-na¨ıve PD
from controls (chi square = 2.71; 𝑃 = 0.09).
Of the 8 patients with PD that had a PA, 1 had it during
the first phase of the test, 2 during the placebo infusion, and
5 during the CMI challenge. All the 6 controls had the onset
of the PA during the CMI infusion.
The mean MFVs for each group were compared for each
phase of the test and no statistically significant difference was
found (data not shown).
As therewas no specific response toCMI for diagnosis, we
split the sample into two groups: those who had panic during
the test (panickers) and those who had not (nonpanickers).
At the first direct visual observation of the blood velocity
graphics, the sudden drop of MFV at both the right and left
MCAs was clearly visible during a PA (Figure 1).
The average MFVs during each different phase of the test
were compared between panickers and nonpanickers and no
statistically significant difference was found during any phase
of the test, for both right and left MCAs (Table 1).
The highest MFV variations clearly distinguished pan-
ickers from nonpanickers, in the right as well as in the left
MCA, both using absolute and relative (%MFV variations
from baseline) values (Table 2).
Comparing averageMFV values during the CMI infusion
period to those obtained during baseline conditions, statis-
tically significant differences were found when comparing
panickers to nonpanickers when panickers were compared
to nonpanickers. For right MCA, we found an average
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Table 1: Comparison of average MFV values in the four phases of
the test (CMI values split also into CMI1 and CMI2) for both left and
right middle cerebral arteries, between panickers and nonpanickers.
Mean MFV (cm/sec)
𝑃
Panickers (𝑛 = 14) Nonpanickers (𝑛 = 23)
Baseline
RMCA 67.2 67.2 0.99
LMCA 70.5 67.5 0.53
Placebo
RMCA 67.1 67.1 0.99
LMCA 71.5 65.4 0.21
CMI1
RMCA 67.2 67.3 0.97
LMCA 70.3 65.3 0.33
CMI2
RMCA 63.6 68.9 0.30
LMCA 67.9 66.8 0.84
CMI
RMCA 65.6 68.0 0.64
LMCA 69.3 65.9 0.52
Wash
RMCA 68.3 68.2 0.98
LMCA 70.4 65.6 0.48
MFV: mean flow velocity; RMCA: right middle cerebral artery; LMCA: left
middle cerebral artery; CMI: clomipramine.
Table 2: Comparison between panickers and nonpanickers for





(𝑛 = 23) 𝑃
Highest MFV variation
(cm/sec)
RMCA −16.92 ± 9.96 −6.45 ± 5.40 <0.001
LMCA −15.41 ± 8.64 −6.14 ± 4.95 <0.001
Highest % MFV variation
RMCA −24.31 ± 14.12 −10.31 ± 7.87 0.001
LMCA −20.56 ± 11.44 −9.61 ± 6.91 0.001
Data expressed as mean ± standard deviation.
MFV: mean flow velocity; RMCA: right middle cerebral artery; LMCA: left
middle cerebral artery.
MFV difference of −1.49 ± 3.44 cm/sec in panickers and
of 0.90 ± 3.02 cm/sec for nonpanickers (𝑃 < 0.05). For left
MCAwe found ameanMFVdifference of−2.25± 5.17 cm/sec
in panickers and of 0.57 ± 2.58 cm/sec in nonpanickers (𝑃 <
0.05).
3.2. Discussion. The basic finding of this research is a signif-
icant drop of MFV in both right and left MCAs during the
onset of a PA performing a provocative challenge with CMI.
CMI challenge has not been frequently used in literature as a
provocative test to induce PAs in a clinical setting [38]. In our
study, CMI did not seem to be a challenge specific to PD, as
it induced PAs in both PD patients and control subjects.
In contrast with other results [42] that reported increased
bilateralmiddle and anterior cerebral artery and left posterior
cerebral artery velocity at rest, our findings showed no
difference in MCAs’ MFV, between the three groups at
baseline conditions.
It is notable that none of the subjects with a previous
lifetime treatment with antidepressants, even if drug-free
when performing the test, reported a PA during the chal-
lenge. Whether this is due to a sort of in vivo exposure
to antidepressant side effect, cognitively mediated, or to a
long lasting decreased sensitivity to the anxiogenic effect
of acute administration of serotoninergic agents cannot be
ascertained.
Although TCD actually measures the blood flow velocity
in the large arteries, it is commonly accepted that a reduction
of flow velocity is associated with the vasoconstriction of
the microcirculation supplied by that artery. The bilateral
acute decrease of MFV during a PA found in this study
suggests the vasoconstriction of the microcirculation of deep
brain structures perfused by MCAs and involved in the
neuroanatomy of fear [49, 50].
This finding should not be secondary to the effects of CMI
challenge. This statement is confirmed by two observations.
We had the opportunity to study MFV pattern of three
patients who experienced a PA outside the period of CMI
infusion (one during baseline conditions and two during
placebo infusion) and these subjects showed the same pattern
of response of those who panicked during CMI infusion.
On the other hand, none of the subjects who did not
have a PA showed any MFV modification while performing
the challenge. Some studies reported that severe anxiety
decreases CBF [51, 52]. The observation that this kind of
response is specific for acute anxiety and not for PD is
confirmed by the fact that in our study no difference in MFV
modifications was found when comparing PD subjects with
controls.
Our data seem to be consistent with the hypothesis of
an autonomic nervous system dysregulation involved in the
pathogenesis of PD. Several lines of evidence suggest this
relationship. First of all, most of the somatic symptoms of
panic attacks are mediated by the autonomic nervous system.
Many studies have reported a variety of autonomic
dysfunctions in patients with PD (e.g., [53, 54]); these include
excessive autonomic nervous system activation and reactivity,
functional modifications of the parasympathetic and sym-
pathetic systems, and changes in 𝛼 and 𝛽 adrenoreceptor
function. However, other studies did not confirm the role of
the autonomic nervous system in PD [55, 56].
It could be hypothesized that the MCV modifica-
tions observed in the present study could be due to
hyperventilation-induced hypocapnia. In fact, the relation-
ship between the decrease in CBF velocities and panic-
induced hyperventilation/hypocapnia is well established (for
a review see [57]). In our study, PaCO
2
was not measured
and the device used to continuously monitor respiratory
rates did not allow data recording. This represents the main
limitation of the work, as it was not possible to perform
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multivariate statistical analyses adjusted for these variables.
However, although factors such as the respiratory volume or
the presence of “shallow breathing”may influence the PaCO
2
,
thus making the respiratory rate a not perfect correlate of
PaCO
2
, the continuous qualitative observation of heart and
respiratory rates during the test suggested for us that MFV
drop occurs immediately before the onset of tachycardia and
hyperventilation in every subject that panicked during the
test. This suggests a strong association between microcircu-
lation vasoconstriction and the onset of a PA, regardless of
the influence of other possible confounding factors.
4. Conclusion
Despite the above limitations, the present study suggests
that cerebral homeostatic dysfunctions may have a key role
in the onset of a PA. These data support the hypothesis
that an autonomic dysregulation can be the trigger of panic
symptoms occurrence [44, 53, 54]. However, replication
studies examining the PaCO
2
, or at least the respiratory rate,
are warranted in order to better understand the possible
etiopathogenetic mechanisms underlying panic attacks.
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